Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack
According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events beyond one year in patients with a history of a prior heart attack. Researchers also identify a low-bleeding risk group among whom the clinical benefit of vorapaxar was particularly favorable. This research is presented at the European Society of Cardiology Congress 2012 and published simultaneously in the Lancet.
For more than a million Americans who survive a heart attack each year, doctors routinely prescribe a daily aspirin to help prevent the formation of blood clots in the arteries which can frequently lead to another heart attack. Other platelet blockers, like clopidogrel, which also serve this purpose, are often added for up to a year, but the scientific evidence is unclear about whether adding platelet blockers to aspirin beyond this timeframe is clinically useful. Despite such therapies, these patients have an almost 15 percent chance of having another atherosclerosis-related event that brings them to the hospital within a year.
"There continues to be substantial uncertainty regarding the benefit of long-term antiplatelet therapy in addition to aspirin in patients with prior heart attacks," said Benjamin M. Scirica, M.D., M.P.H., investigator at the TIMI Study Group, a cardiologist at BWH, and one of the study's investigators. "This is the first study to show convincingly that continued, long-term, therapy beyond one year with more potent antiplatelet therapy reduces the risk of having another cardiovascular event." Previous studies in secondary prevention did not show this benefit.
Researchers from the TIMI Study Group at BWH have shown, for the first time, that adding vorapaxar, a new antiplatelet medication, on top of standard therapy which includes aspirin, is effective for long-term secondary prevention in stable patients with a prior heart attack. When used with aspirin and other standard antiplatelet therapy in a broad group of patients with previous heart attack, vorapaxar reduced the risk of cardiovascular death, heart attack or stroke by an additional 20 percent.
This randomized, double blind, placebo-controlled, multinational study followed 26,449 patients for more than two years while receiving standard antiplatelet therapy for established atherosclerosis, including previous heart attack, stroke or atherosclerotic narrowing in the arteries of the legs. Participants were randomly assigned to receive the investigational platelet blocker (2.5 mg orally once daily) with standard therapy, or a placebo with standard therapy. The overall trial results, which were presented and published in March 2012, demonstrated a 13 percent reduction in the risk of cardiovascular death, heart attack or stroke. These new findings focus specifically on the 17,779 patients with a prior heart attack.
Vorapaxar is the first of a new class of investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonists. Unlike other antithrombotic drugs, vorapaxar blocks thrombin from stimulating platelets to stick together and create clots. In addition to the benefit of reducing future cardiac events, researchers also report that this new therapy was found to increase the risk of moderate or severe bleeding in patients with prior heart attacks. Intracranial hemorrhage tended to be higher but did not differ significantly between vorapaxar than placebo (0.6 vs. 0.4 percent at 3 years),
Researchers caution that if vorapaxar becomes available for clinical use, clinicians will have to balance the antithrombotic efficacy versus the risk of bleeding for the individual patient.
"Of the groups we studied, the greatest net clinical benefit was observed in those patients who are less than 75 years old, have no history of stroke or transient ischemic attacks, and weigh at least 60 kilograms," said Scirica. "In this group of 14,909 patients, 84 percent of the group with prior heart attacks, vorapaxar reduced the risk of cardiovascular death, heart attack, or stroke by 25 percent and cardiovascular death alone by 27 percent."
Journal reference: The Lancet
Provided by Brigham and Women's Hospital
- New class of platelet blockers proves effective in phase III trial Mar 26, 2012 | not rated yet | 0
- Merck blood thinner shows mixed results: study Mar 24, 2012 | not rated yet | 0
- New platelet blocker reduces blood clots, artery-opening procedures Jun 21, 2012 | not rated yet | 0
- Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks Sep 26, 2011 | not rated yet | 0
- Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events Mar 26, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
why is dielectric breakdown damaging?
5 hours ago Dielectric break down... i understand that there is current passing through the insulator but why is this damaging to the insulator? please go as...
Radiation from a charged harmonic oscillator
10 hours ago Anyone know if there are any graphical simulations online for the field of a charged harmonic oscillator, or better yet maybe some kind of paper on...
Relating physics forces and entropy
22 hours ago Consider proton and electron are seperated in space at some finite distance.Now suppose they released then the decrease in potential energy equals...
Force Between Two Concentric Solenoids
May 25, 2013 Imagine a finite length solenoid with outer radius R1 and inner radius R2. This solenoid has a time-varying current going though it. This solenoid is...
Synchrotron, question about insertion devices and electron velocity
May 25, 2013 When an electron enters an insertion device (wiggler and undulator) from the storage ring in a synchrotron the tangential velocity is equal to the...
Equating differentials => equating coefficients
May 25, 2013 Hi all, In thermodynamics one often has equations like A dx + B dy = ∂f/∂x dx + ∂f/∂y dy From which follows A = ∂f/∂x B = ∂f/∂y
- More from Physics Forums - Classical Physics
More news stories
Serelaxin may be more effective for relieving dyspnea in heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from RELAX-AHF presented in today's late ...
Cardiology 11 hours ago | not rated yet | 0
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Cardiology May 25, 2013 | 5 / 5 (1) | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
Cardiology May 25, 2013 | not rated yet | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Cardiology May 25, 2013 | 5 / 5 (7) | 5
Transcatheter aortic valve implantation (TAVI) is effective and safe in Asian patients, according to early experience based on first results from a multicentre Asian registry reported at EuroPCR 2013.
Cardiology May 24, 2013 | not rated yet | 0
Neuroscientists from Cold Spring Harbor Laboratory, led by Assistant Professor Adam Kepecs, have linked the activity of two types of brain nerve cells, neurons, to decisions made during particular type of ...
9 hours ago | 5 / 5 (2) | 0 |
Researchers at the Stanford University School of Medicine have identified mutations in several new genes that might be associated with the development of spontaneously occurring cases of the neurodegenerative disease known ...
9 hours ago | 5 / 5 (1) | 0 |
Humans and most mammals can determine the spatial origin of sounds with remarkable acuity. We use this ability all the time—crossing the street; locating an invisible ringing cell phone in a cluttered bedroom. ...
9 hours ago | 5 / 5 (1) | 0 |
A new way of tackling cancer and predicting tumor virulence are has been reported by a French team of scientists from the Institut Albert Bonniot de Grenoble including researchers from CNRS, Inserm and Université Joseph ...
6 hours ago | 5 / 5 (1) | 0
(HealthDay)—Each summer, lawn mower accidents send countless numbers of people to the emergency room. Mishaps often involve serious injuries to the fingers, hands and feet. Often caused by a moment's distraction, ...
9 hours ago | not rated yet | 0